Recent Company News

• 06:17 PM ET Dec 03, 2025
  

  Eisai presents new data on continued and expanding benefit of LEQEMBI at CTAD conference (¥4683.0000, 0)

• 07:38 PM ET Dec 01, 2025
  

  Eisai presents new data from E2814-103 study of etalanetug at CTAD 2025 (¥4688.0000, -102)

• 08:42 AM ET Dec 01, 2025
  

  Germany's IQWiG says additional benefit of lecanemab compared to previous standard of care in Germany has not been proven

• 12:45 AM ET Nov 28, 2025
  

  Eisai applies in Japan for approval of Leqembi as drug with new administration route (09:32 JT/01:32 CET/19:32 ET) (¥4894.0000, -1)

• 07:38 AM ET Nov 25, 2025
  

  Eisai completes rolling submission to U.S. FDA for LEQEMBI IQLIK sBLA as subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track Status (¥5023.0000, 0)

• 10:11 PM ET Nov 24, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:05 PM ET Nov 18, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 06:40 PM ET Nov 18, 2025
  

  Eisai to present new data on lecanemab at CTAD conference to be held in San Diego 1-Dec to 4-Dec (¥4579.0000, 0)

• 06:43 PM ET Nov 13, 2025
  

  BioArctic's Leqembi approved for once every four weeks IV maintenance dosing for treatment of early Alzheimer's disease by MHRA in the UK (SEK 288.60, 0.00)